The FDA says Onyx Pharmaceuticals (ONXX) hasn't conducted the necessary trials to get a quick review of its cancer drug carfilzomib, and instead will have to settle for a standard review period. Shares -8% premarket.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/